key: cord-0723881-iffqc4bw authors: Darif, Dounia; Hammi, Ikram; Kihel, Ayyoub; El Idrissi Saik, Imane; Guessous, Fadila; Akarid, Khadija title: The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong? date: 2021-02-18 journal: Microb Pathog DOI: 10.1016/j.micpath.2021.104799 sha: aa308012cf69f3cbbad2acb87a1621540d2170e7 doc_id: 723881 cord_uid: iffqc4bw The outbreak of coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, has emerged in China in December 2019 and rapidly spread to more than 196 countries worldwide. The physiopathology of human SARS-CoV-2 has not been completely understood, but its pathogenesis has been linked to a disproportionate response of the immune system. Just as described for SARS and MERS, an uncontrolled systemic inflammatory response, known as cytokine release syndrome (CRS) was observed in severe COVID-19 patients. It results from the release by immune and non-immune effector cells of substantial amounts of pro-inflammatory cytokines and appears to contribute to SARS-CoV-2 pulmonary inflammation and extensive lung damage. In addition, hyper-coagulation and thrombosis resulted from the important release of pro-inflammatory cytokines contribute to the lethality of subjects severely infected with SARS-CoV-2. It is therefore essential to have a deep understanding of the various cytokines involved in this exacerbated immune response, and that could be targeted by potential immunological treatments. The aim of this review was to gather the current knowledge about the role of pro-inflammatory cytokines, namely IL-1β, IL-6, IL-8, IL-17 and TNFα in SARS-CoV-2 CRS, the probable causes and clinical outcomes of this phenomenon in severe cases of COVID-19. J o u r n a l P r e -p r o o f 1. Introduction 49 In December 2019, a new corona virus appeared, the SARS-CoV-2 which belongs to the Tumor necrosis factor (TNF-α), the most studied cytokine in the TNF superfamily, is another 177 key factor in the COVID-19 CRS pathophysiology. It is produced by several cell types, 178 including macrophages, mast cells, T cells, epithelial cells, and smooth muscle cells in the 179 airways. Its synthesis is mainly stimulated by PAMPs and IL-1, via NF-κB activation, and also 180 IL-17 [29] . In healthy subjects, inhaling TNF-α triggers bronchial hyper-responsiveness and 181 inflammation of the airways induced by increased neutrophils recruitment. This cytokine can 182 also cause T cells apoptosis [30] . TNF-α promotes the production of other cytokines such as the 183 IL-1β and IL-6 [31]. Many studies have found that severe COVID-19 cases display increased 184 plasma levels of TNF-α [32, 33, 34] . Such increase was also associated with disease severity and 185 inversely correlated with the reduction of T lymphocytes [21] . It has been reported that the 186 prevalence of severe and complicated cases of COVID-19 was lower in patients with anti-TNF-α 187 therapy compared to patients taking steroids. Only 15% of patients with COVID-19 treated with 188 anti-TNF-α had to be hospitalized, and very few of them required an intensive care 189 unit/ventilator or died (3%) compared to patients treated with oral or parenteral steroids and, who 190 had to be hospitalized in 67% of the cases and admitted to the intensive care unit, or died in 25% 191 of the cases [35] . Two additional case reports supported this evidence: one patient suffering from 192 ileal Crohn's disease affected by COVID-19 and was under steroid therapy, and another patient 193 with Crohn's ileitis treated with Adalimumab, a human monoclonal antibody that blocks the 194 interaction between TNF-α and its soluble, membrane-bound receptors [36, 37] . To date, a single 195 randomized controlled trial of Adalimumab has been registered (ChiCTR2000030089). especially in mesenchymal and endothelial cells; thus, promoting the infiltration of 207 immunocompetent cells into injured tissue [40] . 208 IL-1β is secreted during the inflammasome activation in response to several pathogens including 209 viruses such as Coronaviruses. Indeed, a previous study showed that the SARS-CoV Viroporin 210 3a was sufficient to induce the NLRP3 inflammasome activation and IL-1β production in 211 macrophages stimulated by LPS [41] . A recent investigation showed that IL-1β is highly 212 produced in plasma from both severe and non-severe COVID-19 cases compared with non-213 infected subjects [33] . Furthermore, another study showed that IL-1β transcripts were 214 significantly up-regulated in whole blood from COVID-19 patients [42] . The increase of IL-1β 215 production is the downstream indicator of cell pyroptosis; this latter is a highly inflammatory 216 form of programmed cell death commonly seen with cytopathic viruses. Therefore, pyroptosis 217 plays a major role in SARS-CoV-2 pathogenesis and is likely a trigger for the subsequent There is recent evidence that TH17 is involved in acute respiratory distress syndrome. The was also detected in COVID-19 dead patients' plasma [33] . [58]. In addition, the clinical and laboratory characteristics of COVID-19 patients showed that 281 IL-8 was strongly produced in severe, rather than non-severe cases [33] . IL-8 is also known to Almost all types of tissues express ADAM17 but its activity is strictly regulated. By shedding 307 ACE2, ADAM17 inhibits Ang 1-7 production, and increases the level of Ang II in COVID-19 308 patients. The ACE2 down-regulation is associated with RAS imbalance, increased pro- TNFα, another CRS member, is synthesized as a membrane-protein, and also cleaved to release Clinical and immunological features of severe and moderate coronavirus disease 700 2019 Clinical features of 704 patients infected with 2019 novel coronavirus in Wuhan, China Dysregulation of immune response in patients with COVID-19 in Wuhan Current Summary Data A fatal case of COVID-19 712 pneumonia occurring in a patient with severe acute ulcerative colitis T cell interleukin-17 induces stromal cells to 754 produce proinflammatory and hematopoietic cytokines Proinflammatory Outcome of Antiviral Response in Human Cells Combination of IL-17 and TNFα induces a pro-760 inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells Interleukin-6 (IL-6) and Promote Viral Persistence by Inhibiting Cellular Apoptosis and Cytotoxic T Cell 764 COVID-19 associated with acute respiratory distress syndrome COVID-19 in an elderly patient treated with 770 secukinumab Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 784 infection is associated with disease severity and fatal outcome COVID-19 severity correlates with airway epithelium-immune cell 792 interactions identified by single-cell analysis The role of chemokines in neutrophil biology Neutrophil extracellular COVID-19: Coagulopathy, Risk of Thrombosis, and the 897 Rationale for Anticoagulation With SARS-CoV-2 RNA and Are Hyperactivated in COVID-19 Coagulation and anticoagulation in COVID-19 Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at 911 autopsy in COVID-19: A case series Effects of IL-1β, IL-6 and IL-8 on erythrocytes, platelets and clot 914 viscoelasticity Pathological inflammation in patients with COVID-19: a key role 916 for monocytes and macrophages Prominent changes 919 in blood coagulation of patients with SARS-CoV-2 infection risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a 924 retrospective cohort study Pathological 928 evidence of pulmonary thrombotic phenomena in severe COVID-19 COVID-19 cytokine storm: the interplay between inflammation and 931 coagulation Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization Management of corona virus disease-943 19 (COVID-19): the Zhejiang experience, Zhejiang Da Xue Xue Bao. Yi Xue Ban Gut microbiota may underlie the predisposition of healthy 949 individuals to COVID-19 Microbiota-dependent signals are required to sustain TLR Mitochondria and microbiota 956 dysfunction in COVID-19 pathogenesis Toxic Shock Syndrome SARS and MERS: Recent 962 insights into emerging coronaviruses Systematic 965 Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 966 and SARS-CoV Plasma inflammatory cytokines 981 and chemokines in severe acute respiratory syndrome MERS-CoV 984 infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile IFN-I response timing relative 988 to virus replication determines MERS coronavirus infection outcomes • IL-6, IL-1β, TNF-α, IL-17, IL-8 are involved in COVID19 cytokine release syndrome.• Cytokines exacerbation participates in thrombo-embolism associated with poor outcome.• CRS may be due to pyroptosis, microbiota alteration or delayed IFN response. ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relation ships which may be considered as potential competing interests:The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.